Tags: LungCancer, Genetics
Tags: LungCancer, TargetedTherapy, Genetics
Tags: BasicResearch, Genomics, LungCancer
Dr. Pasi Jänne led a study that showed a drug shrank lung tumors in 61 percent of patients whose cancers had developed the T790-M resistance mutation. He also commented on personalized medicine for cancer patients.
Tags: LungCancer, TargetedTherapy
Tags: BasicResearch, LungCancer
Dr. Pasi Janne led a study showing a new targeted drug as a promising treatment for advanced lung cancers.
Dr. Pasi A. Jänne commented on Bristol-Myers Squibb’s new cancer drug, Opdivo, which is working so well that its clinical trial in lung cancer will be stopped two years ahead of schedule.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: